Ceramic resurfacing: the future and challenges

Danielle de Villiers, Laura Richards, Michael Tuke, Simon Collins

MatOrtho Ltd, Leatherhead, Surrey, KT22 7BA, UK

Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Danielle de Villiers. MatOrtho Ltd, 19/20 Mole Business Park, Randalls Road, Leatherhead, Surrey, KT22 7BA, UK. Email: danielle.devilliers@matortho.com.

Abstract: Ceramics have a history of use in total hip replacement (THR) including early use in hip resurfacing. Improvements in ceramics over the past two decades have resulted in the BIOLOX® delta material which has a higher fracture resistance, low wear and excellent biocompatibility compared to other orthopaedic biomaterials. Cobalt Chromium Molybdenum (CoCrMo) metal alloy continues to be used in hip resurfacing but is generally limited to use of larger sizes in active males due to a legacy of concerns with metal ion release from discontinued devices and large diameter modular head trunnions. A novel hip resurfacing device (ReCerf®, MatOrtho Ltd., UK) utilises BIOLOX® delta, removing CoCrMo metal from the prosthesis. ReCerf® is based on a clinically successful design from the same manufacturer (ADEPT®, MatOrtho Ltd., UK) and although BIOLOX® delta is a clinically proven material in THR, it requires significant testing to prove safety in the clinical environment. Increasing regulations particularly in Europe, has increased the time to market for new devices such as this and whilst the changes are being implemented to ensure the lowest risk for patients, they are also leaving patients unable to access new treatment routes. Ultimately, it is long term clinical outcomes that are required to determine whether the future of resurfacing is in using alternative materials such as ceramic and whether these compare favourably with the established, successful metal designs which have been in clinical use for over 20 years.

Keywords: Hip resurfacing; ceramics; design; regulatory

Received: 02 December 2019; Accepted: 19 December 2019.
doi: 10.21037/aoj.2019.12.11

View this article at: http://dx.doi.org/10.21037/aoj.2019.12.11

The history of ceramics in resurfacing

A variety of materials have been used in resurfacing including early generation ceramics. Table 1 describes some of the earliest hip resurfacing devices which utilised alumina ceramic. The majority of these devices only used ceramic in the femoral side and many early devices had the limitation of a polyethylene acetabular cup. The majority of failures in these early hip resurfacing cases are cited for loosening caused by particle-induced-osteolysis. Polyethylene material properties are now better controlled through sterilisation in an inert atmosphere, cross-linking and use of antioxidants, but do still wear (5). There were no cases of femoral loosening reported for the cemented Furuya alumina ceramic resurfacing components (4) but the cementless all-ceramic Salzer device reported 5 incidences of femoral loosening out of a total of 16 implantations (3). Despite evidence that alumina ceramic in total hip replacement (THR) can fail due to component fracture when abnormally loaded (6), reports of fracture in these early design hip resurfacing devices has not been found. The alumina ceramic used in these early hip resurfacing designs was significantly weaker than the current generation of BIOLOX® delta.

In 1990, hip resurfacing re-emerged in the form of the McMinn Hip (made by Corin Medical—designed by Derek McMinn with Finsbury Orthopaedics) then in 1997 the
Birmingham Hip Replacement (BHR, Midland Medical Technologies designed by McMinn with and made by Finsbury Orthopaedics, bought by Smith and Nephew in 2006 but manufactured by Finsbury Orthopaedics until 2008), learning from previous manufacturing and materials. Several other metal-on-metal (MoM) devices were subsequently released to the market following early success but most of these were subsequently withdrawn due to design differences. Outside of patient selection, the factors contributing to the success or failure of a MoM hip resurfacing device are now acknowledged to include: different bearing clearances, different metallurgy, poorer quality control of manufacturing tolerances, inadequate head coverage of the cup when implanted at steep inclination angles, different operative techniques, and accelerated commercial rollout with poor training. Currently we believe that only two MoM hip resurfacing devices remain CE marked: the BHR and the ADEPT® (MatOrtho, previously Finsbury Orthopaedics Ltd., UK).

The potential reaction of the body to excessive Cobalt and Chromium of MoM bearings is however a continuing concern following reports of hypersensitivity reactions, aseptic lymphocyte-dominated vasculitis-associated lesions (ALVAL) and pseudotumour (8-10). Nevertheless hip resurfacing is used in limited numbers, mostly for active young male patients with good femoral bone, for whom these implants perform well. There are therefore several patient groups including women for whom resurfacing is not generally considered a good option despite good bone stock which is removed for conventional hip replacement. This has led to several investigations of alternative materials for use in resurfacing to replace MoM for all patients (11-13).

**Design and development of ReCerf®**

ReCerf® hip resurfacing (MatOrtho Ltd., UK) is exclusively manufactured for MatOrtho from BIOLOX® delta ceramic (CeramTec, Plochingen, Germany), Figure 1. BIOLOX® delta ceramic is a zirconia toughened alumina which is an established articulating surface used as a ceramic-on-ceramic (CoC) bearing surface in THR for over 16 years and has shown clinically low wear rates with excellent biocompatibility (14). BIOLOX® delta as a hip resurfacing bearing could make this a treatment option suitable for a greater range of patients. However this material as a bearing couple is clinically unproven in hip resurfacing devices but has been used in bearing diameters up to 48 mm as developed by MatOrtho’s predecessor, Finsbury Orthopaedics, in the DeltaMotion THR. The use of

### Table 1 Historical resurfacing materials and designs

<table>
<thead>
<tr>
<th>Device name, year reported (ref)</th>
<th>Femoral material</th>
<th>Acetabular material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinamed Custom, 2009</td>
<td>Alumina ceramic</td>
<td>N/A</td>
</tr>
<tr>
<td>ICLH, 1990 (1)</td>
<td>Alumina ceramic</td>
<td>Polyethylene</td>
</tr>
<tr>
<td>Wagner, 1978 (2)</td>
<td>Alumina ceramic or cobalt chromium molybdenum alloy</td>
<td>Polyethylene</td>
</tr>
<tr>
<td>Salzer, 1978 (3)</td>
<td>Alumina ceramic</td>
<td>Alumina ceramic</td>
</tr>
<tr>
<td>Furuya, 1978 (4)</td>
<td>Alumina ceramic</td>
<td>Polyethylene</td>
</tr>
</tbody>
</table>

**Figure 1** ReCerf® ceramic-on-ceramic resurfacing (patents pending).
this material in larger diameters for hip resurfacing is an incremental step-wise innovation.

ReCerf® was designed with an experienced group of hip resurfacing surgeons and based on the clinically proven ADEPT®, to be available in 2 mm increments from sizes 40 to 64 mm bearing diameter. The resurfacing heads feature three internal pockets and two circumferential grooves to maximise primary cementation stability. Head thickness and stem size increase with bearing diameter. The stem is proportional to head diameter to maximise bone volume and reduce the potential for stress shielding. The cups utilise direct fixation to bone through a titanium and hydroxyapatite coating (DeltaFix®) with an inference fit at the equator and a constant 163° coverage angle across all sizes. The coating is applied using vacuum plasma spray on the as-fired ceramic as characterized as to ISO 13179-1 and 13379-2 for titanium and hydroxyapatite coatings, respectively. Tensile and shear adhesion tests to ASTM F1147 and ASTM F1044 showed bonding strengths comparable or greater than bonding to medical grade titanium alloy under static and fatigue conditions. Of further interest was that the adhesion bond strengths were comparable between as-fired and polished surfaces. The ReCerf® bone to coating interface is effectively therefore the same as found on most modern modular lined cups and the coating adhesion tests allay potential concerns of debonding although longer term clinical data is required.

Despite the long-term intended use of the device only two ISO standards (ISO 14242 and ISO 7206-12) were identified as relevant for testing for regulatory body’s assessment under the medical device directive (MDD). Additional finite element and mechanical tests were therefore developed to ensure the safety of the device. Over the three year development cycle, 15 finite element studies and some 40 mechanical tests were conducted with CeramTec and Aurora Medical Ltd, Southampton UK. Numerous cadaver labs were conducted with the development surgeon team. These tests were designed to mitigate risks associated with fracture, fixation, stress shielding, wear, and surgical technique.

Novel simulation tests developed included comparisons of the BIOLOX® delta ceramic ReCerf® and CoCrMo ADEPT® devices to consider the materials’ behaviour and deformations during cadaveric implantation (12,13). Finite element studies were conducted comparing bone remodelling when implanted with a CoCrMo or BIOLOX® delta monobloc cup (15). The remodeling stimulus of the acetabular and femoral bone when implanted with BIOLOX® delta was of particular importance as the ceramic has a Young’s modulus 1.6 times greater than CoCrMo which could lead to increased stress shielding. However, finite element studies showed that the bone strain remained similar whether the device implanted was metal or ceramic suggesting that it is only magnitudes of Young’s modulus differences which change the bone’s response (15). Tests considering the ceramic material in isolation and head/cup design were also conducted showing BIOLOX® delta to be low wearing at diameters of 64mm even under microseparation conditions (16). Worst-case edge loaded impact tests were performed with the equivalent of car crash impacts, known to fracture the pelvis (17). New instrumentation was required including a patented cup impaction cap and handle which allowed for direct grip of the outer diameter of the cup without requiring compromise to the cup integrity or damaging pelvic bone, Figure 2. Finite Element Analysis of the stresses induced on the ceramic cup by the novel impactor, mechanical tests and surgeon cadaver sessions indicated suitability for safe clinical use.

Clinical and regulatory perspective

All testing with critical safety factors applied demonstrated suitability for the intended use of ReCerf® and demonstrated equivalence against the predecessor device, ADEPT®. Many regulatory systems worldwide are based on the European regulatory framework and require CE

Figure 2 Cup impaction cap directly gripping the outer diameter of the ceramic cup (patent pending).
mark for entry into these markets. After a lengthy review period by the MatOrtho’s regulating notified body the CE mark application was rejected on the grounds of no other all-ceramic resurfacing device being available. This despite initially being advised that the CE mark was achievable through equivalency routes with independently approved monitoring of an almost identical predecessor design, accompanied with a substantial testing programme, and use of the most biocompatible proven ceramic material couple offering a metal ion free solution to the most widely documented concern with resurfacing technology. Major changes in the regulatory landscape in Europe were being introduced early and now require a fully approved limited Clinical Investigation before wider EU release. This requires a dataset having much reduced patient numbers to that proposed in the CE submission that voluntarily proposed a 500 patient limit reviewed by Beyond Compliance prior to wider release. Companies who seek to innovate medical devices now face serious challenges to any further innovation as discussions with the competent authorities and notified bodies have failed to answer what constitutes a viable introduction to prove safety and performance for orthopaedic devices. The increasing scrutiny of the impending EU medical device regulations (MDR) is already presenting further challenges to introduce innovation and threaten the viability of existing successful devices. The British Orthopaedic Association has itself highlighted the real risk that products will be more expensive, some will disappear due to commercial viability alone and the requirement for clinical investigations may not produce a relevant clinical or ethical route to relevant scientific data (18).

Other countries’ regulatory authorities have recognised the potential for ReCerf® to treat patients for whom other hip replacement devices are not appropriate when considering age, bone preservation, gender and metal sensitivity. Approved use of ReCerf® has been granted via Humanitarian access to a small number of trained hip resurfacing surgeons and this has allowed access to this device for patients seeking more optimised treatment than that currently available under standard regulatory pathways. The countries in which ReCerf® has been implanted to date are Australia, South Africa, Canada and Belgium. This humanitarian access route has been directly denied by the MHRA in the UK. It remains unclear what number of cases are required to show the show safety of a device and the new MDR regulations require constant monitoring of clinical outcomes throughout the lifetime of the device thus increasing the challenges to obtain European approvals. To date (December 2019) 117 implantations have taken place with several patients approaching up to 1 year post-surgery and reporting a return to activity, Figure 3. There has been 1 revision for acetabular component malposition at 3 months.

**Discussion**

Metal-on-Metal hip resurfacing use peaked in the late 2000s before issues surrounding the effects of metal wear debris became apparent. With patients living longer and having more active lifestyles, the typical expectations of a hip replacement have changed to include increased longevity, minimally invasive surgical options and increased functionality. There is a growing body of evidence that suggests hip resurfacing can offer better function in patients with similar aspirations for sports, more normal gait and push off forces when compared to a THR (19-24). Hip resurfacing also has lower risk of infection and dislocation as compared to THR (25). The registry data results and long term surgeon series are now starting to demonstrate fewer revisions than were or might have been expected (26). Resurfacing is therefore a suitable treatment for many patients but the CoCrMo material currently used limits the population of patients who can receive this device and a more benign ceramic material with the potential for lower wear than any prior hip resurfacing articulation could benefit all.

*Figure 3 X-ray showing the ReCerf® implantation (courtesy of Prof Paul Beaule).*
In summary, MatOrtho Limited has developed an innovative device that could combine the benefits of hip resurfacing with the proven material properties of BIOLOX® delta ceramics. ReCerf® Hip Resurfacing System is an all-ceramic hip resurfacing device based on MoM hip resurfacing and this includes similar functional geometries, cup coverage angle and use of the same instrumentation and operative technique. The proven hip resurfacing design (ADEPT®, MatOrtho Ltd.) has 13 years of successful clinical use and the BIOLOX® delta ceramic material has excellent outcomes in THR over 16 years. Combining proven design and this material may offer patients an alternative treatment to those currently available but which have limitations.

The cost to develop a novel device is substantially increasing, even for one, as in this case, very similar to an existing device (Adept®). ReCerf® received substantial input from several disciplines such as engineers (design, test, production), material scientists and clinicians over 3 years development and underwent extensive pre-clinical testing, much beyond standardised testing requirements for long-term devices and to date, there have been 117 ReCerf® implantations worldwide with no implant related adverse effects. A further two years has now been lost trying to navigate an unclear regulatory system as regulations change. Regulatory frameworks in the EU now make it increasingly challenging to make any progress for new devices, even when in this case changes are incremental, use no novel materials or processes and are specifically designed to reduce the known risks associated with metal. The requirement for a very limited clinical investigation is contributing to a further delay for patients receiving innovative medical treatments that need careful studies with statistically sensible numbers.

Acknowledgments

None.

Footnote

Conflicts of Interest: All authors are employees of MatOrtho Ltd.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


doi: 10.21037/aoj.2019.12.11